PDB43 PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH  by Schmidt, WE et al.
Abstracts A105
where mean BMI was lowest (Italy). CONCLUSIONS: Weight control is an important 
aspect of management of T2DM. This requires accurate assessment and agreement of 
patient weight and BMI levels by treating physicians and their patients. Accurate
risk stratiﬁ cation based on weight and BMI may help improve effective communica-
tions and disease management decisions between T2DM patients and their treating
physicians.
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OBJECTIVES: New treatments for T2D are needed to improve glycemic control,
reduce side-effects, and improve patient satisfaction. Liraglutide is an OD human
GLP-1 analog that has beneﬁ ts as monotherapy, or in combination with OADs. 
METHODS: The Liraglutide Effect and Action in Diabetes 6 (LEAD-6) trial was an 
open-label trial comparing liraglutide to exenatide as add-on to OADs. Adults with 
T2D on metformin and/or sulfonylurea and A1C 7–11% were randomized to liraglu-
tide 1.8 mg OD or exenatide 10 Mg BD for 26 weeks. This was followed by a 14-week
extension phase, in which all patients received liraglutide 1.8mg OD. RESULTS:
During weeks 0–26, A1C reductions were signiﬁ cantly greater and the incidence of 
hypoglycemia was signiﬁ cantly lower in the liraglutide-treated group. Patient Reported 
Outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Ques-
tionnaire status (DTSQs) at week 0, 26, 34 and 40 and DTSQ change (DTSQc) at
week 26 and 34. The overall treatment satisfaction was highest with liraglutide (p 
0.0001); DTSQs score increased from 27.4 at baseline to 32.1 at week 26 compared 
to exenatide (increase from 27.6 to 29.3). All items on DTSQs except ‘understanding’ 
(ie ‘current treatment’, ‘convenience’, ‘ﬂ exibility’, ‘recommend’, ‘continue’) improved
signiﬁ cantly more with liraglutide than exenatide. The proportion of ‘satisﬁ ed’ patients 
(deﬁ ned as DTSQc  6) was 94% in liraglutide, 86% with exenatide (p  0.0176). 
Patients perceived a greater reduction in hypoglycemia at week 26 with liraglutide 
(DTSQc 0.9) than with exenatide (0.4; p  0.0193) and a greater reduction in per-
ceived hyperglycemia (1.0, 0.3, respectively; p  0.0007). During the extension 
phase, when all patients received liraglutide, DTSQs scores remained stable in patients 
who continued on liraglutide and had increased signiﬁ cantly (p  0.0131) at week 40 
in those who switched from exenatide to liraglutide at week 26. CONCLUSIONS:
These results demonstrate signiﬁ cant improvements in patients’ treatment satisfaction 
with liraglutide compared to exenatide.
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OBJECTIVES: To examine the impact of insulin initiation on the DSC-R in patients 
with type 2 diabetes (T2D). METHODS: We administered the DSC-R to T2D patients 
enrolled in a large insulin clinical trial (acronym: DURABLE) at baseline prior to 
starting insulin and at six months post-insulin initiation. The trial compared the efﬁ -
cacy and safety of insulin initiation with lispro mix 75/25 versus insulin glargine. The
DSC-R is a T2D-speciﬁ c measure that assesses the occurrence and the perceived burden 
of the following eight T2D-related symptoms: hypoglycemic, hyperglycemic, cardio-
vascular, neuropathic/pain, neuropathic/sensory, psychological/fatigue, psychological/
cognitive, and ophthalmologic/vision. Summary score for each domain ranged from
0–100 with higher scores indicating greater symptom burden. We compared change
in mean score (baseline to six months) for two insulin arms combined together. Effect
size (ES; cohen’s d) and analysis of covariance were used to examine the extent and 
signiﬁ cance of change. Effect sizes of 0.2, 0.5, and 0.8 represent small, medium, and 
large degrees of change, respectively. RESULTS: A total of 576 patients completed the
DSC-R at both time points. The mean age, duration of diabetes, A1c, and percent
female at baseline were 57.0 years, 9.6 years, 8.9%, and 41%, respectively. Baseline 
mean scores ranged from 24.2 (cardiovascular and neuropathic/pain) to 45.9 (psycho-
logical/fatigue). The mean scores at 6 months ranged from 22.6 (ophthalmologic/
vision) to 40.7 (psychological/fatigue). Absolute changes in the mean domain score 
ranged from 0.6 (neuropathic/sensory) [p  0.45; ES  0.02] to 9.8 (hyperglycemic) 
[p  0.0001; ES  0.38; small to medium effect]. Other domains with ES q0.20 were 
psychological/fatigue and psychological/cognitive. CONCLUSIONS: Initiation of 
insulin therapy was associated with a small to moderate improvement in hyperglyce-
mic symptoms domain. Small effects were also observed in psychological/fatigue and
psychological/cognitive domains.
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OBJECTIVES: Diabetes is a debilitating and common illness that can lead to signiﬁ -
cant disability. Key patient-reported outcomes are important as they can inﬂ uence
productivity and patient health-related quality of life (HRQL). The objectives of the 
current research were to: (1) assess the current level of treatment satisfaction within
existing oral anti-diabetics (OADs) and (2) determine the association between treat-
ment satisfaction and productivity and HRQL. METHODS: The current study design 
was a cross-sectional web-based survey of adults diagnosed with type 2 diabetes mel-
litus (T2DM) using OADs, but not insulin. Treatment satisfaction was assessed using
the Diabetes Medication Satisfaction questionnaire (DiabMedSat). HRQL was exam-
ined with the EQ-5D instrument. The Work Productivity and Activity Impairment 
(WPAI) and Diabetes Productivity Measure (DPM) questionnaires were used to assess 
productivity. Pearson’s correlations and linear regression models were used to assess 
strength and direction in association. RESULTS: Of 2,074 survey respondents, 53%
were men and mean age was 60 years (SD  10.83). 64% of respondents report being 
very/extremely satisﬁ ed with their diabetes treatments. Total DiabMedSat score was 
79.5; higher scores were reported with the burden subscale (89.5) versus the efﬁ cacy 
and symptom (i.e. tolerability) sub-scales (69.8 and 69.5). There was a direct correla-
tion between overall treatment satisfaction and higher EQ-5D scores (r2  0.401, 
p  0.001), and increased work and life productivity (DPM: r2  0.595 and r2  0.640, 
p  0.001). Similar correlation results were observed with WPAI. After controlling
for patient demographics, treatment satisfaction has greater effects on presenteeism
(impairment while working) (WPAI: 0.472, 95% CI: 0.611 to –0.333, p  0.001) 
than absenteeism (missed work time) (WPAI: 0.057, 95% CI: 0.157 to 0.043, p 
0.263). CONCLUSIONS: Among T2DM patients, there is a high level of satisfaction
with OAD therapies, though improvements could be made in efﬁ cacy and tolerability. 
Increases in treatment satisfaction can have a direct improvement on productivity and 
health-related quality of life.
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OBJECTIVES: To assess the relationship between patients’ expectations about and 
experiences with insulin therapy, and how they contribute to overall treatment satisfac-
tion. METHODS: The Expectations about Insulin Therapy (EAITQ) and the Experi-
ence with Insulin Therapy Questionnaires (EWITQ) were administered at baseline and 
endpoint, respectively, to insulin-naïve patients with type-2 diabetes in a randomized 
controlled trial comparing treatment algorithms for an inhaled insulin. Pearson 
correlation coefﬁ cients were calculated between EAITQ and EWITQ scores and 
patient characteristics and patient reported outcomes measures. Wilcoxon Signed 
Rank test was used to compare EAITQ and EWITQ item score distributions. Differ-
ences between EAITQ and EWITQ scores were calculated to categorize patients 
into three groups according to the extent to which their expectations about insulin
therapy were met by experiences (i.e., not met, met, and exceeded). Oneway analysis
of variance with Scheffe post-hoc tests was performed to detect differences in treatment
satisfaction scores among the three groups. RESULTS: EAITQ and EWITQ data
were available for 240 patients (male: 61% male, age: 58 (mean) years old, diabetes
duration: 10 years, HbA1c: 8.4%). More positive expectations were signiﬁ cantly
associated with greater self-efﬁ cacy (p  0.01); more positive experiences were signiﬁ -
cantly associated with shorter diabetes duration, less symptom distress and greater 
well-being, self-efﬁ cacy, and treatment satisfaction (p  0.01). Overall, patients’ 
experiences with insulin therapy were signiﬁ cantly more positive than their 
expectations, with 58% of patients’ experiences exceeding expectations, 29% experi-
ences met by expectations, and 13% experiences less than expectations. Post-hoc
tests indicated that diabetes treatment satisfaction scores were signiﬁ cantly different
among the three groups with higher scores associated with the exceeding of exp-
ectations by experiences. CONCLUSIONS: Expectations may not independently 
impact treatment satisfaction, but their relationship with experiences signiﬁ cantly
contributes to treatment satisfaction. The EAITQ and EWITQ may be useful tools
for clinicians in identifying differences in expectations and experiences concerning
insulin therapy.
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OBJECTIVES: Diabetes symptoms and tolerability issues of existing treatments may 
affect work productivity, contributing to the overall burden of type-2 diabetes mellitus 
(T2DM). Objectives were to document the frequency of diabetes symptoms and 
tolerability issues among existing oral antidiabetic drugs (OAD) and determine their
